We used a modified reference microdilution method (the M-38P method) to evaluate the in vitro activities of the new triazole UR-9825 in comparison with those of amphotericin B against 77 strains of opportunistic filamentous fungi. UR-9825 was clearly more active than amphotericin B against all fungi except Fusarium solani and Scytalidium spp. Notably, UR-9825 had low MICs for Aspergillus fumigatus and Paecilomyces lilacinus (MICs at which 90% of isolates are inhibited, 0.125 g/ml for both species).The incidence of opportunistic infections caused by molds is continuously increasing, and such infections can be severe and difficult to treat, especially in immunocompromised patients. Immunosuppressive and cytotoxic therapies and hematological malignancies, among others, are important risk factors for such infections (6,12,18). Nowadays, the options for treatment of opportunistic infections are still led by amphotericin B and, to a lesser extent, a few azole derivatives, which frequently fail. For this reason the development of new potent and broadspectrum antifungal agents is an important challenge for modern medicine. UR-9825 is a new triazole with a potent, broad spectrum of antifungal activity, good pharmacokinetics, and excellent bioavailability ( In the study described here we have compared the in vitro activities of this compound and those of amphotericin B against 77 clinically important filamentous fungi from our collection (Facultat de Medicina de Reus). They included 10 isolates of Aspergillus fumigatus, 11 isolates of Aspergillus flavus, 11 isolates of Aspergillus niger, 10 isolates of Fusarium solani, 10 isolates of Paecilomyces variotii, 10 isolates of Paecilomyces lilacinus, 10 isolates of Chaetomium globosum, 2 isolates of Scytalidium lignicola, and 3 isolates of Scytalidium dimidiatum. Isolates were retrieved from storage in water or slant cultures covered with sterile parafin oil and were subcultured on potato dextrose agar plates at 35°C for 7 to 10 days and, in the case of C. globosum, on oatmeal agar plates at 25°C for 15 days (9). P. variotii ATCC 36257 was included as the quality control strain, and it was tested in each series. UR-9825 and amphotericin B were provided as pure powders by J. Uriach & Co. (Barcelona, Spain) and the U.S. Pharmacopeia (Rockville, Md.), respectively. Both drugs were dissolved in dimethyl sulfoxide (Panreac Química S.A., Barcelona, Spain) and diluted in RPMI 1640 buffered with morpholinepropanesulfonic acid (MOPS) to a final concentration range of 16 to 0.03 g/ml. The inocula were prepared by scraping the sporulated fungi from the agar plates with a loop and suspending them in sterile saline solution. The fungal suspensions were filtered once through sterile gauze to remove the hyphae. For the preparation of ascospores and conidial suspensions of C. globosum and Aspergillus spp., respectively, we used 0.05% Tween 20 (Panreac Química S.A.) in sterile saline solution. The resulting suspensions were vigorously vortexed and adjusted spectrophotometrically ( ϭ 530 nm) to ...